De-risk your program with evidence-based secondary pharmacology insights
Safety issues account for about a quarter of the attrition in drug projects and can…
Certara2021 年 5 月 28 日
Stakeholder perspectives: current and potential benefits
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Certara2021 年 5 月 26 日
Strengths and opportunities for HTAs and market access in Europe through case studies
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Certara2021 年 5 月 26 日
Similarities and differences between SNDS and other claim databases
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Certara2021 年 5 月 25 日
Using Authoring Templates to Write the Right Way
Creating submission-ready regulatory documents that are consistent in presentation, appropriate in content, and formatted to…
Certara2021 年 5 月 25 日
Overview of SNDS and the key working practices to access the database and ongoing SNDS developments
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Certara2021 年 5 月 25 日
PBPK modeling approaches to assess risks associated with bioequivalence in drug development
In this webinar, Dr. Ioannis Loisios-Konstantinidis from Novartis, Switzerland discussed: Opportunities and challenges in conducting…
Certara2021 年 5 月 19 日
Why Your Regulatory Writers Need eCTD Authoring Templates
If you’ve heard about eCTD authoring template suites before, but you’re not sure what they…
Certara2021 年 5 月 14 日
Opening a debate on open‐source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate
As model‐informed drug development becomes an integral part of modern approaches to the discovery of…
Certara2021 年 5 月 13 日
Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics
Perhaps the most important lesson learned from the COVID‐19 pandemic is that of preparedness. Enhanced…
Certara2021 年 5 月 11 日
